Investigating new treatments for Alzheimer's disease using potassium channel blockers
Optimization of Novel Potassium Channel Kv1.3 Blockers with Potential as Alzheimer's Disease Therapeutics
This study is looking at new medications that block certain potassium channels to see if they can help reduce inflammation in the brain and improve memory and daily life for people with Alzheimer's disease.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hager Biosciences, LLC NIH-funded |
| Lab location | 1 site (Bethlehem, United States) |
| Project ID | NIH-10920282 on NIH RePORTER |
What this research studies
This research focuses on developing novel potassium channel blockers that may help treat Alzheimer's disease, a condition that primarily affects older adults. The study aims to understand how these blockers can modulate neuroinflammation, which is a significant factor in the progression of Alzheimer's. By targeting specific channels in the brain, the research seeks to restore balance in inflammatory responses that contribute to cognitive decline. Patients may be monitored for changes in cognitive function and overall quality of life as part of the research.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that improve cognitive function and quality of life for individuals with Alzheimer's disease.
How similar studies have performed: While the approach of targeting potassium channels is relatively novel, similar strategies in modulating neuroinflammation have shown promise in other neurodegenerative conditions.
Where this research is happening
Bethlehem, United States
- Hager Biosciences, LLC — Bethlehem, United States (Active)
Researchers
- Principal investigator: Butera, John a — Hager Biosciences, LLC
- Study coordinator: Butera, John a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.